HR5032-119

What This Bill Does

The Nitazene Control Act adds benzimidazole-opioids commonly called nitazenes to Schedule I of the Controlled Substances Act. The class covers substances, salts, isomers, and salts of isomers substantially similar to etonitazene or isotonitazene, with a benzimidazole core, benzyl or substituted benzyl group, basic nitrogen-containing side chain, and mu-opioid receptor agonist activity. Listed examples include etonitazene, clonitazene, metonitazene, isotonitazene, protonitazene, butonitazene, etodesnitazene, flunitazene, N-pyrrolidino etonitazene, N-desethyl isotonitazene, and N-piperidinyl etonitazene. Substances temporarily scheduled become permanently scheduled as of enactment. The Attorney General, in consultation with HHS, may issue rules clarifying the nitazene class. Existing researchers working under an active IND or other FDA or DEA-recognized exemption with prior IRB approval can continue without immediately obtaining a Schedule I registration if they notify the Attorney General within 90 days; that transition lasts up to 18 months while expedited registration applications proceed.

Who Benefits and How

Public health agencies benefit from permanent Schedule I control of a class of potent synthetic opioids linked to overdose risk. Drug enforcement agents benefit from a class-wide nitazene definition covering substantially similar substances and named examples. Communities affected by opioid overdoses benefit if permanent scheduling reduces unlawful nitazene distribution. Existing nitazene researchers benefit from an 18-month transition window and expedited registration process.

Who Bears the Burden and How

Nitazene traffickers face Schedule I criminal and regulatory consequences for substances in the defined class. Legitimate researchers must notify the Attorney General within 90 days and apply for Schedule I registration within the transition period. DEA registration staff must expedite qualifying applications to avoid disrupting existing approved research. Attorney General rulemaking staff must consult HHS if clarifying rules are needed for the nitazene class.

Key Provisions

• Adds nitazene benzimidazole-opioids to Schedule I of the Controlled Substances Act.
• Permanently schedules substances that were temporarily scheduled before enactment.
• Authorizes Attorney General rules clarifying the class in consultation with HHS.
• Provides an 18-month transition for existing IND or exempt IRB-approved research after 90-day notice.
• Bars initiation of new nitazene research without proper registration and scheduling compliance.